DR Trials

Question 1

WESDR

Answer 1

Incidence /prevalence / progression / RF in DR under treatment
Hba1c , Duration of DM

Question 2

DCCT ?

Answer 2

Tight glycemic control Vs complications of DM in type 1
Primary and secondary prevention in mild DR

Question 3

DCCT C/I

Answer 3

Old age
CAD
Children

Question 4

EDIC ?

Answer 4

Epidemiology of diabetes interventions and complications
10 year F/U in DCCT

Question 5

UKPDS

Answer 5

United Kingdom prosepective diabetes study
Tight glycemic control in type 2 diabetes vs complications
Tight BP control on
Stroke, vision loss,Diabteic complications
Noted reduction in progression and systemic comorbidities

Question 6

DRS

Answer 6

Diabteic retinopathy study
In PDR and NPDR severe
Argon vs xenon laser or observation

Highlights :
Reduced VA LOSS BY 50 %
Identified HRPDR
add PRP USES

Question 7

ETDRS

Answer 7

early treatment DRS
Argon laser 1. Early to severe stage
2 aspirin in DR progression
3 effect on DME
4 PRP timing

Results
Provided CSME definition
Severity grading of DR

OUTCOMES :
5 week treatment course , 4month follow up
ME with less severe DR = immediate focal laser with delayed scatter
ME with more severe DR = immediate PRP WITH focal laser
Aspirin has no affection on DRP
Risk factors requiring high rates of vitrectomy
Early treatment over deferred laser on vision loss

Question 8

DRCR B

Answer 8

Doses two of IVTA vs focal laser on CI DME
CMT and VA
Immediate - IVTA
Intermediate- Equivalent
Later and long run - Focal laser / grid (lesser complications )

Question 9

DRCR C

Answer 9

CMT in DME
Diurnal variation of CMT IN DME

Question 10

DRCR D

Answer 10

D= Die = End
Vitrectomy in DME PATIENTS with moderate vision loss and VMT C ERM removal

Question 11

DRCR H:

Answer 11

High vs low dosing on BVZ and PG
BVZ > PG IN CMT reduction in 3 months as well better VA in 12 weeks

Question 12

DRCR I

Answer 12

RanI bizumab : deferred and prompt laser» IVTA with prompt laser
Pseudophakes reverse holds the right

Question 13

DRCR S

Answer 13

PDR =S - severe
Anti vegf alone Vs standard prompt PRP
VA and severe vision loss equivalent
DME AND VFD better with anti vegf group
Safety same

Question 14

DRCR T

Answer 14

T = three anti vegf
Aflibercept vs bevacizumab vs ranibizumab
VA similar effects ~ presenting baseline vision acuity
Mild VA at onset = similar effects on VA and CMT
SEVERE VISION LOSS AT onset = aflibercept over all others
Saftey same

Question 15

FAME

Answer 15

Fluocinide acetonide (varying doses ) on DME
Not approved with FDA
Increased risk of ocular complications
BCVa and VA similar results

Question 16

MEAD

Answer 16

D- dexamethason intravitreal inserts
Varying concentrations vs sham injection
Equivalent in reducing CMT and safety

Question 17

PLACID

Answer 17

PL = laser Photocogaulation with sham injection
D - dexamethsasone with LASER
IN DIFFUSE DME
dexa with laser PDR preferred in BCVa improvement

Question 18

CHAMPLAIN

Answer 18

P = PPV
DEXA in postvitrectimized eyes with DME
Improved VA and vascular leakage in DME